Clinical Trial Update: Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated concomitant administration of a new hexavalent vaccine with a meningococcal serogroup C vaccine in healthy infants during primary seri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections
• Neisseria Meningitidis Disease

Drugs mentioned

• Hexavalent vaccine (Sanofi Pasteur)
• Meningococcal serogroup C conjugate vaccine (Neisseria meningitidis serogroup C conjugate vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Neisseria Meningitidis, Bacterial Infections | Phase 3 | Status: COMPLETED